Immunome (IMNM) Non-Current Debt (2020 - 2021)

Immunome (IMNM) posted Non-Current Debt of $134000.0 for Q1 2021, little changed on a QoQ basis from $134000.0 in Q4 2020.

Immunome (IMNM) Non-Current Debt (2020 - 2021) Analysis & Trends

Immunome's Non-Current Debt history runs 2 years deep, the most recent figure standing at $134000.0 for Q1 2021.

Quarterly Non-Current Debt changed N/A year-over-year to $134000.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $134000.0 (changed N/A YoY) and the FY2020 annual result came in at $134000.0, changed N/A from the prior year.
Non-Current Debt was $134000.0 for Q1 2021 at Immunome, roughly flat from $134000.0 in the prior quarter.
Across five years, Non-Current Debt topped out at $195000.0 in Q3 2020 and bottomed at $134000.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	105.94 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	842.92 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Immunome	2.49 Bn	1.91 Bn	-	-

Download Data